CCL3 and tuberculosis: More importantly, we propose new candidates to be used in serum (TGFα, IL-7) or saliva (MIP1α, VEGF, GRO, MCP-1) to differentiate different TB study groups and biomarker combinations with promising discriminatory capacity that could set the basis for point-of-care tests based on affordable platforms.